Open access
Aug 2026
A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges
Promising histologic gains must now be translated into reduced morbidity and mortality through an ambitious agenda of long-term outcome trials, precision biomarkers, and equitable, multidisciplinary care models.
Zhi-Fu You, Ling-Long Yang, Yuan-Hao Long et al.
· Frontiers in Pharmacology · 1 citation